VivoSeq
Cardiovascular

Vascular Malformation

9

Pipeline Programs↗

2

Active Trials↗

7

Companies Involved↗

Vascular Malformation is an early-stage landscape with 9 programs across 7 companies. The most active players are Novartis, Watson Pharmaceuticals, SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany. 2 programs are in Phase 3.

Intelligence

Pipeline Metrics

Competitive Density

36/100

Pipeline Velocity

0/100

Mech. Concentration

40/100

Completion Rate

75/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Novartis logo

Novartis

2 programs

Phase 2W

Watson Pharmaceuticals

1 program

Phase 2S

SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany

1 program

Phase 2H

Haihe Biopharma Co., Ltd.

1 program

Phase 2P

Prism Pharmaceuticals

1 program

Phase 3Bristol-Myers Squibb logo

Bristol-Myers Squibb

2 programs

Phase 3

Pipeline

Programs by Phase

Analysis

Modality Breakdown

89%

Small molecule

8 of 9 classified programs — the dominant modality here.

11%ALL OTHERSMonoclonal antibody111%

Small molecule leads; the ring shows all 9 classified programs, each share of the total. Modality classified for 100% of 9 pipeline programs.

Analysis

Trial Status

12

clinical trials

Completed6 · 50%
Unknown status2 · 17%
Withdrawn2 · 17%
Recruiting2 · 17%

Clinical Trials

Trial Activity

12 trials

An Open-Label, Single-Arm Exploratory Clinical Study of Everolimus for the Treatment of Vascular Malformations
Recruiting·XXuanwu Hospital, Beijing·Phase 2·NCT07037238·10 enrolled
A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Recruiting·MMurdoch Childrens Research Institute·Phase 2·NCT05983159·50 enrolled
the Efficiency of Thalidomide for Recurrent Small Intestinal Bleeding Due to Gastrointestinal Vascular Malformation
Completed·SShanghai Jiao Tong University School of Medicine·Phase 3·NCT02707484·150 enrolled
Bupropion and Specific Cardiovascular Malformations
Completed·GSK logoGSK·N/A·NCT01165255·7,005 enrolled
Efficacy and Safety of the Mammalian Target of Rapamycin (mTor Rapamycin) Inhibitor in Vascular Malformations
Completed·CCliniques universitaires Saint-Luc- Université Catholique de Louvain·Phase 3·NCT01811667·19 enrolled
Efficacy and Safety of Bevacizumab for the Treatment Hemorrhagic Hereditary Telangiectasia (HHT) Associated With Severe Hepatic Vascular Malformations. Phase II Study
Completed·HHospices Civils de Lyon·Phase 2·NCT00843440·25 enrolled
Long-term Effects of Thalidomide for Recurrent Gastrointestinal Bleeding Due to Vascular Malformation
Completed·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT00964496·55 enrolled
suPERficial Slow-flow Vascular malFORMations Treated With sirolimUS
Completed·UUniversity Hospital, Tours·Phase 2·NCT02509468·63 enrolled
Efficacy Study of Thalidomide in Gastrointestinal Vascular Malformation Related Bleeding
Withdrawn·SShanghai Jiao Tong University School of Medicine·Phase 2·NCT02754960
Retreatment and Its Efficiency of Thalidomide for Vascular Malformation Patients With Failure of First Course Treatment
Withdrawn·—·Phase 2·NCT02301949
Role of Sirolimus in Treatment of Microcystic , Mixed Lymphatic and Vascular Malformations
Unknown status·SSohag University·N/A·NCT06160739·10 enrolled
Treatment of Congenital Vascular Malformations Using Sirolimus: Improving Quality of Life
Unknown status·RRadboud University Medical Center·Phase 3·NCT03987152·75 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)